FDA clears BioSphere Embosphere microspheres:
This article was originally published in Clinica
The US FDA has cleared BioSphere Medical's Embosphere Microspheres for the treatment of hypervascularised tumours and arteriovenous malformations. The microspheres are used to occlude the blood supply to the diseased tissue in a process known as embolotherapy. BioSphere has already received marketing approval for the microspheres in Canada, Australia and Europe for use in general embolisation procedures and has begun a Phase I study in the US of their use in uterine artery embolisation for the treatment of uterine fibroids.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.